This article is more than 5 years old. Information may no longer be current.

Topical MMC more effective than topical azelastine for allergic conjunctivitis, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW DEHLI, India — Topical azelastine is not as effective as topical mitomycin-C for the treatment of allergic conjunctivitis, results of a short-term study have found.

Punita Kumari Sodhi, MS, DNB, and colleagues here with Safdarjung Hospital randomized 63 patients with allergic conjunctivitis to receive topical azelastine 0.02% or topical mitomycin-C four times daily for 3 months. Follow-up exams were completed at 2 weeks to examine side effects of the medications and at 4 weeks to assess treatment outcomes.

More patients in the MMC group had relief of symptoms such as redness, photophobia, discharge and foreign body sensation than the patients in the azelastine group. More patients in the azelastine group had relief of lacrimation and pain than those in the MMC group. Both drugs were equally effective at reducing itching symptoms. The mean age of the patients in the MMC group was statistically higher than those in the azelastine group.

The study is published in the March issue of Cornea.